|
May 28
|
Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe
|
|
Oct 10
|
European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
|
|
Jun 18
|
Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe
|
|
Mar 22
|
Alvotech Announces Increase in Number of Own Shares
|
|
Mar 22
|
Analysts Expect Breakeven For Alvotech (NASDAQ:ALVO) Before Long
|
|
Jan 10
|
STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara
|
|
Jan 3
|
Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea® (aflibercept)
|
|
Nov 29
|
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
|
|
Nov 28
|
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update
|
|
Nov 10
|
STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara
|
|
Nov 7
|
Alvotech to Present at the Jefferies 2023 London Healthcare Conference
|
|
Sep 5
|
Alvotech Announces Changes to the Leadership Team
|